Economic evaluation of Wolbachia deployment in Colombia: A modeling study

Donald S. Shepard,Samantha R. Lee,Yara A. Halasa-Rappel,Carlos Willian Rincon Perez,Arturo Harker Roa

DOI: https://doi.org/10.1101/2024.07.01.24309774

2024-07-05

Abstract:Background and Aims Wolbachia are bacteria that inhibit dengue virus replication within the mosquito. A cluster-randomized trial found Wolbachia reduced virologically-confirmed dengue cases by 77% and previous models predicted Wolbachia to be highly cost-effective in Indonesia, Vietnam, and Brazil.  in Colombia, Wolbachia was introduced in the Aburrá Valley in 2015 and Cali in 2020.  To inform decisions about future extensions, we performed economic evaluations of the potential expansion of Wolbachia deployments to 11 target Colombian cities. Methods We assembled quantities and the distribution by severity of reported dengue cases from Colombia’s national disease surveillance system and the health service provision registry (RIPS).  An epidemiological panel of three experts estimated the shares of non-medical cases and adjustments for under-reporting and misclassifications. We determined costs (in 2020 US dollars) of treating dengue illness from the benchmark insurance tariff, RIPS data on treatment services per symptomatic dengue case, and the national government database for establishing insurance premiums. A cluster randomized trial quantified the effectiveness of Wolbachia against symptomatic dengue cases. Results Projecting impact over 10 years for Cali, we estimated a net health-sector savings of USD4.95 per person.  We also estimated averting 369 disability-adjusted life years (DALYs) per 100,000 population.  From a societal perspective, at 10 years Wolbachia deployment is expected to have highly favorable benefit-cost ratios, with benefits per dollar invested of $5.50 in Cali and USD4.68 over all target cities. Conclusions Over 10 years, Wolbachia is highly beneficial on economic grounds, and almost universally cost saving.  That is, Wolbachia’s savings in health care costs alone would more than offset deployment costs nationally and in 9 target cities (those with adjusted annual dengue incidence at least 50/100,000 population). In these 9 target cities, Wolbachia would generate at least USD3.00 in benefits per dollar invested, giving substantial confidence that Wolbachia deployment would be cost-beneficial in Colombia.

What problem does this paper attempt to address?

The paper primarily discusses the cost-benefit analysis of implementing the Wolbachia mosquito release strategy in Colombia to control dengue fever. Specifically, the research aims to:

1. **Evaluate the effectiveness of Wolbachia in Colombia**: By introducing mosquitoes infected with the Wolbachia bacteria to suppress the replication of the dengue virus within them, thereby reducing the incidence of dengue fever cases.

2. **Economic evaluation**: Conduct a cost-benefit analysis of expanding the scale of Wolbachia releases in 11 target cities in Colombia to determine whether this strategy is economically viable and to provide a basis for future decision-making.

3. **Methodology**: The study collected data from the Colombian national disease surveillance system, including the number of reported dengue fever cases and the distribution of their severity, and adjusted the number of unreported cases through expert assessment. At the same time, the direct costs of treating dengue fever cases and the implementation costs of the Wolbachia project were calculated. Based on the results of previous research, it is assumed that Wolbachia can significantly reduce the incidence of dengue fever.

4. **Results**: The study indicates that over a 10-year period, the deployment of Wolbachia is expected to bring significant cost savings to the health sector in Colombia (approximately $4.95 saved per person over 10 years), prevent a large number of disability-adjusted life years (DALYs), and from a societal perspective, the return on investment is very high (for example, in the city of Cali, every $1 invested can yield a return of $5.50).

5. **Conclusion**: The study believes that within 10 years, the Wolbachia strategy is economically very beneficial and almost universally cost-saving. Specifically, the savings in healthcare costs alone are sufficient to offset all the costs of implementing the Wolbachia project in 9 target cities (with an annual incidence of dengue fever of at least 50 per 100,000 people), and for every $1 invested in these cities, at least $3.00 in benefits can be obtained, providing ample confidence for the promotion of Wolbachia in Colombia.